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  Cancer stem cells (CSCs) are often characterized by the elevated expression of drug-resistance related 
stem-cell surface markers, such as CD133 and ABCG2. Recently, we reported that CSCs have a high 
level of expression of the IL-6 receptor (IL-6R). The purpose of this study was to investigate the effect 
of anticancer drugs on the expression of the drug resistance-related cancer stem cell markers, ABCG2, 
IL-6R, and CD133 in non-small cell lung cancer (NSCLC) cell lines. A549, H460, and H23 NSCLC 
cell lines were treated with the anticancer drugs 5-fluorouracil (5-FU; 25 μg/ml) and methotrexate 
(MTX; 50 μg/ml), and the expression of putative CSC markers was analyzed by fluorescent activated 
cell sorter (FACS) and the gene expression level of abcg2, il-6r and cd133 by reverse transcriptase- 
polymerase chain reaction (RT-PCR). We found that the fraction of ABCG2-positive(＋) cells was 
significantly increased by treatment with both 5-FU and MTX in NSCLC cells, and the elevation of 
abcg2, il-6r and cd133 expressions in response to these drugs was also confirmed using RT-PCR. Also, 
the number of IL-6R(＋) cells was increased by MTX in the 3 cell lines mentioned and increased by 
5-FU in the H460 cell line. The number of CD133(＋) cells was also significantly increased by both 
5-FU and MTX treatment in all of the cell lines tested. These results indicate that 5-FU and MTX 
considerably enhance the expression of drug-resistance related CSC markers in NSCLC cell lines. Thus, 
w e  s u g g e s t  t h a t  a n t i m e t a b o l i t e  c a n c e r  d r u g s ,  s u c h  a s  5 - F U a n d  MT X ,  c a n  l e a d  t o  t h e  p r o p a g a t i o n  
of CSCs through altering the expression of CSC markers. 
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INTRODUCTION
  The cancer stem cell (CSC) theory suggests that tumors 
contain rare subpopulations of undifferentiated cells that 
possess stem cell properties, such as self-renewal, hetero-
geneity, and resistance to anticancer drugs [1,2]. CSCs 
show resistance to chemotherapy because of their low pro-
liferation rate and resistance mechanisms, such as the ex-
pression of multidrug transporters of the ATP-binding cas-
sette (ABC) superfamily. The transporter ABCG2 is known 
to promote resistance to multiple drugs and has been ob-
served in various types of CSCs [3-5]. Due to the drug re-
sistant properties of CSCs, many anticancer drugs show 
transient effects and often do not improve patient prog-
nosis. Even therapies that cause complete tumor regression 
may spare CSCs, allowing for regeneration of the tumor. 
The pentaspan protein, CD133, is a universal marker of 
organ-specific stem cells and tumor-initiating cells. CD133 
was originally identified as a marker for CD34(＋) hema-
topoietic stem and progenitor cells [6] and has been used 
to identify CSCs in several types of cancer [7-11]. Lung can-
cer is the leading cause of cancer death in many countries 
[12]. Poor prognosis of lung cancer patients is due mainly 
to poor response, early relapse, and metastasis after treat-
ment with chemotherapy and radiotherapy. Several studies 
have demonstrated that CD133(＋) lung cancer cells pos-
sess features of stemness and display a higher tumorigenic 
potential than CD133-negative(－) cells [13-15]. CD133 ex-
pression has also been linked to a drug-resistant phenotype 
in lung cancer patients [16].
  In our previous study, lung CSCs, isolated with Hoechst 
33342, were found to express significantly higher levels of 
the IL-6 receptor (IL-6R) and abcg2 [17]. IL-6/IL-6R signal-
ing has been well documented to play a role in the growth 
and malignancy of cancer. The aberrant production and in-
creased secretion of IL-6 in cancer patients is linked to tu-12 H Yi, et al
Table 1. Human primer sequences used for semi-quantitative RT-PCR
Gene Sense primer Antisense primer Product size
abcg2 5’-ACGCCTTGGACAGAATCCAG-3’ 5’-TGGCTCGAGGTATTGTCAGA-3’ 379 bp
il-6r 5’-ACGCCTTGGACAGAATCCAG-3’ 5’-TGGCTCGAGGTATTGTCAGA-3’ 398 bp
cd133 5’-GCATGCAAAAGCCATCATAG-3’ 5’-GGGAATGCCTACATCTGGAA-3’ 446 bp
gapdh 5’-ACCACAGTCCATGCCATCAC-3’ 5’-TCCACCACCCTGTTGCTGTA-3’ 498 bp
mor progression and poor prognosis in many cancer types, 
including lung cancer [18-20]. IL-6 is also known to promote 
multi-drug resistance to chemotherapy [21]. Recently, it 
was reported that the expression of IL-6 and IL-6R in CSCs 
was much greater than in non-CSCs [11,22]. These findings 
suggest that IL-6R is a potential CSC marker related to 
the drug resistance phenotype of some tumors. However, 
the expression of CSC markers and mechanisms by which 
CSCs acquire resistance to many anticancer drugs remains 
unknown. Therefore, we carried out this study to assess the 
effect of anticancer drugs on the expression of the drug re-
sistance-related cancer stem cell markers, ABCG2, IL-6R, 
and CD133 in non-small cell lung cancer (NSCLC) cell lines.
METHODS
Cell culture
  NSCLC cell lines, A549, H460, and H23, were purchased 
from the Korean Cell Line Bank (KCLB; Seoul, Korea). 
Cells were grown in RPMI-1640 medium (Gibco, CA, USA), 
with 10% fetal bovine serum (Gibco, CA, USA) and 1% pen-
icillin/streptomycin (Gibco, CA, USA) in a humidified at-
mosphere at 37
oC with 5% CO2 as recommended by the 
KLCB.
Anticancer drug treatment
  The anticancer drugs, 5-FU and MTX, were purchased 
from Sigma Aldrich Inc. (MO, USA) and dissolved in phos-
phate buffered saline (pH 7.4). NSCLC cells were seeded 
in a 6-well cell culture plate (Corning Inc., NY, USA) and 
incubated overnight in a humidified atmosphere at 37
oC 
with 5% CO2. Cells were then incubated with 5-FU (25 μg/ 
ml) or MTX (50 μg/ml) in media for 6, 12, and 48 hrs prior 
to RT-PCR and for 24 hrs prior to FACS analysis.
FACS analysis
  A549, H460, and H23 NSCLC cells were harvested and 
suspended at a density of 1×10
6 cells/ml in FACS buffer 
containing PBS (pH 7.4) with 2% fetal bovine serum (FBS). 
The cells were incubated with PE-anti-ABCG2 (Abcam, 
MA, USA), FITC-anti-IL-6R (Abcam, MA, USA), and PE- 
anti-CD133 (Miltentyi Biotec, Bergisch Gladbach, Germany) 
antibodies for 30 min. After washing the cells three times 
with FACS buffer, the expression of ABCG2, IL-6R, and 
CD133 were analyzed by fluorescent activated cell sorter 
(FACScalibur; BD, NJ, USA).
RNA extraction and semi-quantitative RT-PCR 
  We performed semi-quantitative reverse transcriptase- 
polymerase chain reaction (RT-PCR) to assess the effect of 
the anticancer drugs on mRNA expressions of abcg2, il-6r, 
and  cd133. Total RNA of the cells was extracted using 
Trizol Reagent (Invitrogen, CA, USA) following manu-
facturer’s directions. Briefly, cells were washed with phos-
phate buffered saline three times and mixed with 1 ml of 
Trizol reagent. The mixture was extracted with 200 μl of 
chloroform. After centrifugation at 10,000×g for 30 minutes, 
the RNA in the aqueous solution was precipitated by adding 
an equal volume of isopropanol. The precipitated RNA was 
collected by centrifugation at 10,000×g for 20 minutes, 
washed by 70% ethanol, dissolved in 20 μl of RNase-free 
water. The amount of RNA was quantified by its absorption 
at 260 nm and stored at －80
oC before use. The house-
keeping gene, glyceraldehyde-3-phosphate dehydrogenase 
(gapdh), was used as an internal control, and the mRNA 
expression of different molecular markers was analyzed by 
a semiquantitative RT-PCR assay. Briefly, first-strand 
cDNAs were synthesized from 5 μg of total RNA using su-
perscript III reverse transcriptase (Invitrogen, CA, USA). 
PCR amplification was performed with specific primer pairs 
designed from published human gene sequences (Table 1) 
using a GeneAmp PCR System 9700 (Applied Biosystems, 
Foster City, CA). 
RESULTS
FACS analysis for the expression of ABCG2, IL-6R, 
and CD133 on the cell surface
  The effect of the anticancer drugs 5-FU and MTX on the 
expression of CSCs markers was studied in A549, H460, 
and H23 NSCLC cell lines using FACS analysis. The frac-
tions of ABCG2(＋), IL-6R(＋), and CD133(＋) cells were 
significantly increased by treatment with 5-FU or MTX in 
these NSCLC cell lines. 
  In vehicle-treated A549 cells, approximately 17% of the 
cells were ABCG2(＋). Following 5-FU and MTX treatment, 
the ABCG2(＋) cell-fraction was significantly increased by 
2.3- and 4.6-fold, respectively (Fig. 1). H460 cells also showed 
a 3.5- and 3.9-fold increase in the number of ABCG2(＋) 
cells in response to 5-FU and MTX, respectively. Also, H23 
cells displayed a 10∼20% increase in the ABCG2(＋) frac-
tion by treatment with 5-FU and MTX compared to control 
treated cells.
  As shown in Fig. 2, the population of IL-6R(＋) cells in 
A549, H460, and H23 were 1.4, 0.04, and 0.74%, respec-
tively. IL-6R(＋) fractions were significantly increased by 
MTX treatment in all 3 cell lines. Alternatively, the IL-6R
(＋) fraction was not increased by 5-FU in A549 and H23 
cells, but H460 cells displayed a large increase in the IL-6R
(＋) cell population. In the 3 NSCLC cell lines tested, the 
CD133(＋) population varied from 0.17% to 0.82% (Fig. 3). 
Specifically, in A549 cells, the CD133(＋) fraction was 
slightly increased by 5-FU or MTX treatment, while the Chemotherapeutics Increase Drug-resistance Related CSC Markers 13
Fig. 1. Analysis of ABCG2 expres-
sion after 5-FU or MTX treatment. 
A549, H460, and H23 non-small cell 
lung cancer cell lines were treated 
with 5-FU (25 μg/ml) or MTX (50 μg/ 
ml) for 24 hours and incubated with 
a PE-anti-ABCG2 antibody. The num-
ber of fluorescent-conjugated cells in 
10
4 cells was analyzed by fluore-
scence activated cell sorter (FACS).
Fig. 2. Analysis of IL-6R expression 
after 5-FU or MTX treatment. A549, 
H460, and H23 non-small cell lung 
cancer cell lines were treated by 
5-FU (25 μg/ml) or MTX (50 μg/ml) 
for 24 hours and incubated with a 
FITC-anti-IL-6R antibody. The num-
ber of fluorescent-conjugated cells in 
10
4 cells was analyzed by fluorescence
activating cell sorter (FACS).
CD133(＋) fractions were markedly increased by 2- to 7-fold 
by 5-FU or MTX treatment in H460 and H23.
RT-PCR gene expression analysis of abcg2, il-6r and 
cd133
The expression of ABCG2, IL-6R, and CD133 was confirmed 
at the mRNA level in the A549, H460, and H23 NSCLC 
cell lines using semi-quantitative RT-PCR (Figs. 4∼6). The 
expression levels of abcg2 and il-6r were increased in the 
3 cell lines following treatment with 5-FU or MTX. As 
shown in Fig. 6, the expression level of cd133 was increased 
in A549 cell line following treatment with 5-FU or MTX.
DISCUSSION
  Various studies have revealed that CSCs develop resist-14 H Yi, et al
Fig. 3. Analysis of CD133 expression 
after 5-FU or MTX treatment. A549, 
H460, and H23 non-small cell lung 
cancer cell lines were treated with 
5-FU (25 μg/ml) or MTX (50 μg/ml) 
for 24 hours and incubated with a 
PE-anti-CD133 antibody. The num-
ber of fluorescent-conjugated cells in 
10
4 cells was analyzed by fluore-
scence activating cell sorter (FACS).
Fig. 4. Gene expression of abcg2
after 5-FU or MTX treatment. (A) 
A549, H460, and H23 non-small cell 
lung cancer cell lines were treated 
with 5-FU (25 μg/ml) or MTX (50 μg/ 
ml) for 6, 12, and 48 hr. After the 
incubation period, total RNA was 
extracted, and mRNA levels were 
analyzed by RT-PCR. PCR amplifi-
cation was performed using specific 
primer pairs designed from publish-
ed human gene sequences. A house-
keeping gene, glyceraldehyde-3-phos-
phate dehydrogenase (gapdh), was 
selected as an internal control. (B) 
The densities of the DNA bands of 
abcg2 were analyzed by Image J 
Software (NIH, http://rsb.info.nih.gov/
nih_image/index.html).
ance to anticancer drugs [3,11,23], but the mechanisms re-
sponsible for this trait have not been well established. In 
our study, 5-FU and MTX treatment increased ABCG2(＋) 
cell populations to a similar extent in 3 NSCLC cell lines. 
Gene expression of abcg2 was also increased by 5-FU and 
MTX treatment. 5-FU has been used to select quiescent or 
slow-dividing stem/progenitor cells based on the fact that 
only rapidly dividing cells are sensitive to 5-FU [24-26]. 
There is growing evidence that CSCs are more resistant 
to 5-FU than non-CSCs [27,28]. This explains why 5-FU 
treatment can spare CSCs, while inducing cell death in can-
cer cells. MTX is a typical substrate of the membranous 
efflux transporter, ABCG2. Therefore, overexpression of 
ABCG2 in cancer cells results in an extensive reduction in 
the amount of MTX absorption, leading to drug resistance 
[29]. Previously, we have shown that lung CSCs have high-
er expression of ABCG2 and display greater resistance to 
MTX than non-CSCs [17,30]. This indicates that treating 
cancer cells with MTX can allow for CSC survival. Although 
we have no direct evidence for the increase of ABCG2(＋) 
cell populations due to 5-FU and MTX, it is speculated that 
these anticancer drugs can induce the expression of the 
ABCG2 transporter, thus sparing drug-resistant CSCs.
  Our results indicate that MTX increased the population 
of IL-6R(＋) cells in A549, H460, and H23 cells, while 5-FU 
increased the IL-6R(＋) population in only H460 cells. 
Although the responses of IL-6R expression to 5-FU treat-
ment were not the same among the 3 NSCLC cell lines test-
ed, the up-regulation of IL-6R(＋) cells by MTX was similar 
in the 3 NSCLC cell lines. Conze et al. demonstrated that Chemotherapeutics Increase Drug-resistance Related CSC Markers 15
Fig. 5. Gene expression of IL-6R
after 5-FU or MTX treatment. (A) 
A549, H460, and H23 non-small cell 
lung cancer cell lines were treated 
with 5-FU (25 μ g/ml) or MTX (50 μ g/ 
ml) for 6, 12, and 48 hr. After the 
incubation period, total RNA was 
extracted, and mRNA levels were 
analyzed by RT-PCR. PCR ampli-
fication was performed using specific 
primer pairs designed from publish-
ed human gene sequences. A house-
keeping gene, glyceraldehyde-3-phos-
phate dehydrogenase (gapdh), was 
selected as an internal control. (B) 
The densities of the DNA bands of 
il-6r were analyzed by the Image J 
Software.
Fig. 6. Gene expression of CD133 after 5-FU or MTX treatment. 
(A) A549, H460, and H23 non-small cell lung cancer cell lines were 
treated with 5-FU (25 μg/ml) or MTX (50 μg/ml) for 12 hr. After 
the incubation period, total RNA was extracted, and mRNA levels 
were analyzed by RT-PCR. PCR amplification was performed using 
specific primer pairs designed from published human gene sequen-
ces. A housekeeping gene, glyceraldehyde-3-phosphate dehydroge-
nase (gapdh), was selected as an internal control. (B) The densities 
of the DNA bands of cd133 were analyzed by the Image J Software.
IL-6 release could promote resistance to chemotherapy [21] 
through the induction of multi-drug resistance 1 (MDR1) 
gene expression [21]. Also, Levina et al. reported that drug 
resistant-CSCs, isolated from H460 NSCLC cell line, have 
significantly elevated levels of IL-6 compared to non-CSCs. 
These reports indicate that IL-6/IL-6R signaling and drug 
resistance are closely related in both cancer cells and cancer 
stem cells. Our results demonstrate that the anticancer 
drugs 5-FU and MTX markedly increased the CD133(＋) 
cell population in 3 NSCLC cell lines. Consistent with our 
results, Sozzi et al. demonstrated that CD133(＋) cells dis-
play stem cell-like features and are resistant to anticancer 
drugs [3]. In addition, Herr et al. showed that CD133(＋) 
cells had a resistance phenotype in lung cancer patients 
[16]. Therefore, these findings suggest that the elevation 
of CSC marker-positive cells by 5-FU or MTX treatment 
results in CSC resistance in NSCLC cell lines. 
  In conclusion, 5-FU and MTX considerably alter the ex-
pression of drug-resistance related CSC populations in the 
NSCLC cell lines A549, H460, and H23. Thus, we suggest 
that antimetabolite cancer drugs, such as 5-FU and MTX, 
can lead to propagation of CSCs by enhancing the ex-
pression of several CSC markers. These findings provide 
a novel mechanism for the highly drug resistant phenotype 
of lung CSCs and their ability to survive chemotherapy.
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